Clinical trial · Interventional
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Development and Validation of Non-Invasive Monitoring Techniques for Postoperative Recurrence and Novel Adjuvant Therapeutic Strategies in Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer. The main questions this study aims to answer are: * How to develop multi-omics-based high-sensitivity detection methods to accurately capture MRD and monitor postoperative recurrence in lung cancer? * Is adaptive treatment guided by ctDNA-MRD for lung cancer patients superior to traditional clinical management and effectively improves survival? * Do heterogeneous patient populations (grouped by stages, histopathological subtypes, driver mutations, and treatment histories) show differences in effects under ctDNA-MRD guided postoperative management strategies?
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adaptive Treatment | — | UNRESOLVED | — |
| Minimal Residual Disease | — | UNRESOLVED | — |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adaptive postoperative management based on minimal residual disease | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- adaptive postoperative management group
- description
- For those who don't receive neoadjuvant therapy, if the MRD testing results after surgery keep negative, postoperative adjuvant therapy will be waived. For those who receive neoadjuvant therapy, if the efficacy reaches pathological complete response(pCR) and MRD testing results keep negative, postoperative adjuvant therapy will be waived. Otherwise, participants will receive a customized treatment plan based on Multi-disciplinary Treatment (MDT).
- interventionNames
- Other: Adaptive postoperative management based on minimal residual disease
- type
- NO_INTERVENTION
- label
- standard clinical postoperative management group
- description
- These participants will receive standard postoperative adjuvant therapy and routine follow-up.
Primary outcomes (1)
- measure
- Two-year recurrence-free survival rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Non-small cell lung cancer with stage IA-IIIA (8th edition TNM classification) planning to undergo curative surgery or to undergo neoadjuvant therapy * Solid nodules \>1 cm or ground-glass nodules \>1.5 cm on imaging * No history of malignancies other than non-small cell lung cancer in the past 5 years * Specimens are well preserved and imaging documents are accessible. Exclusion Criteria: * Age\<18 years old * Non-small cell lung cancer with pathologic stage IIIB-IV (8th edition TNM classification) * Pathology results confirmed not to be non-small cell lung cancer * History of malignancies other than non-small cell lung cancer in the past 5 years
References
Publications (0)
Data not yet available